Innate Pharma S.A.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 31.5 | -100% | -15.14 | -100% |
| P/S |
|
3.87 | 3.24 | 19.42% |
|
|
| P/BV |
|
4.28 | 3.36 | 27.3% |
|
|
| P/FCF |
|
0 | 21.26 | -100% |
|
|
| Ev/Ebitda |
|
-9.96 | 9.95 | -200.15% |
|
|
| Ev/S |
|
3.33 | 1.89 | 76.17% |
|
|
| Ev/FCF |
|
-4.96 | 19.94 | -124.86% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-33.45 | 24.35 | -237.39% | -72.16 | -53.65% |
| ROE |
|
-16.19 | 13.19 | -222.74% |
|
|
| ROA |
|
-4.56 | 6.14 | -174.38% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
-14.66 | 12.56 | -216.72% |
|
|
| ROCE |
|
-47.62 | 14.36 | -431.67% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-2.06 | 6.21 | -133.11% | -5.2 | -60.44% |
| Nеt Debt/Ebitda |
|
1.6 | -5.72 | -127.91% |
|
|
| Debt/Ratio |
|
0.2143 | 0.2122 | 0.9935% |
|
|
| Debt/Equity |
|
0 | 12.49 | -100% |
|
|
| Debt/Net Income |
|
-4.69 | 15.05 | -131.18% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.72 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.27 | -100% | ||
| DSI |
|
0 | 0.7793 | -100% |
|
|
| Average dividend growth |
|
0 | -270.17 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.79 | -100% |
|
|
| Average percentage for payments |
|
0 | 246.79 | -100% |
|
|
| Difference from average difference in sector |
|
-1.72 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-18.41 | 140.59 | -113.09% | ||
| Growth impulse Ebitda in 5 years |
|
-77.91 | 107.17 | -172.7% | ||
| Growth impulse Net Income in 5 years |
|
-60.7 | 123.16 | -149.29% | ||
| Growth impulse FCF in 5 years |
|
24.07 | 93.68 | -74.31% | ||
| Growth impulse EPS in 5 years |
|
-67.14 | 229.02 | -129.32% |
IP Score
2.99/10
